ID   XBP1_HUMAN              Reviewed;         261 AA.
AC   P17861; Q8WYK6; Q969P1; Q96BD7;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 2.
DT   07-APR-2021, entry version 207.
DE   RecName: Full=X-box-binding protein 1 {ECO:0000303|PubMed:2321018, ECO:0000312|HGNC:HGNC:12801};
DE            Short=XBP-1 {ECO:0000303|PubMed:2321018};
DE   AltName: Full=Tax-responsive element-binding protein 5 {ECO:0000303|PubMed:2196176};
DE            Short=TREB-5 {ECO:0000303|PubMed:2196176};
DE   Contains:
DE     RecName: Full=X-box-binding protein 1, cytoplasmic form {ECO:0000303|PubMed:25239945};
DE   Contains:
DE     RecName: Full=X-box-binding protein 1, luminal form {ECO:0000303|PubMed:25239945};
GN   Name=XBP1 {ECO:0000312|HGNC:HGNC:12801};
GN   Synonyms=TREB5 {ECO:0000303|PubMed:2196176},
GN   XBP2 {ECO:0000312|HGNC:HGNC:12801};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION (ISOFORM 1), AND
RP   DNA-BINDING (ISOFORM 1).
RC   TISSUE=B-cell;
RX   PubMed=2321018; DOI=10.1126/science.2321018;
RA   Liou H.-C., Boothby M.R., Finn P.W., Davidon R., Nabavi N.,
RA   Zeleznik-Le N.J., Ting J.P.-Y., Glimcher L.H.;
RT   "A new member of the leucine zipper class of proteins that binds to the HLA
RT   DR alpha promoter.";
RL   Science 247:1581-1584(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION (ISOFORM 1), AND
RP   DNA-BINDING (ISOFORM 1).
RX   PubMed=2196176; DOI=10.1002/j.1460-2075.1990.tb07434.x;
RA   Yoshimura T., Fujisawa J., Yoshida M.;
RT   "Multiple cDNA clones encoding nuclear proteins that bind to the tax-
RT   dependent enhancer of HTLV-1: all contain a leucine zipper structure and
RT   basic amino acid domain.";
RL   EMBO J. 9:2537-2542(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND DNA-BINDING.
RX   PubMed=8349596;
RA   Ponath P.D., Fass D., Liou H.C., Glimcher L.H., Strominger J.L.;
RT   "The regulatory gene, hXBP-1, and its target, HLA-DRA, utilize both common
RT   and distinct regulatory elements and protein complexes.";
RL   J. Biol. Chem. 268:17074-17082(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION (ISOFORM 2),
RP   ALTERNATIVE SPLICING (ISOFORM 2), DNA-BINDING (ISOFORMS 1 AND 2), INDUCTION
RP   (ISOFORM 2), ER STRESS-MEDIATED DOWN-REGULATION (ISOFORM 1), AND DOMAIN
RP   ((ISOFORMS 1 AND 2).
RX   PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0;
RA   Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.;
RT   "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress
RT   to produce a highly active transcription factor.";
RL   Cell 107:881-891(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION (ISOFORM 1), DNA-BINDING (ISOFORM 1), AND INTERACTION WITH FOS
RP   (ISOFORM 1).
RX   PubMed=1903538; DOI=10.1073/pnas.88.10.4309;
RA   Ono S.J., Liou H.C., Davidon R., Strominger J.L., Glimcher L.H.;
RT   "Human X-box-binding protein 1 is required for the transcription of a
RT   subset of human class II major histocompatibility genes and forms a
RT   heterodimer with c-fos.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4309-4312(1991).
RN   [9]
RP   INDUCTION.
RX   PubMed=8627152; DOI=10.1084/jem.183.2.393;
RA   Reimold A.M., Ponath P.D., Li Y.S., Hardy R.R., David C.S.,
RA   Strominger J.L., Glimcher L.H.;
RT   "Transcription factor B cell lineage-specific activator protein regulates
RT   the gene for human X-box binding protein 1.";
RL   J. Exp. Med. 183:393-401(1996).
RN   [10]
RP   FUNCTION (ISOFORM 1), DNA-BINDING (ISOFORM 1), AND DOMAIN (ISOFORMS 1 AND
RP   2).
RX   PubMed=8657566; DOI=10.1093/nar/24.10.1855;
RA   Clauss I.M., Chu M., Zhao J.-L., Glimcher L.H.;
RT   "The basic domain/leucine zipper protein hXBP-1 preferentially binds to and
RT   transactivates CRE-like sequences containing an ACGT core.";
RL   Nucleic Acids Res. 24:1855-1864(1996).
RN   [11]
RP   INDUCTION.
RX   PubMed=10375612; DOI=10.3892/ijo.15.1.173;
RA   Wen X.Y., Stewart A.K., Sooknanan R.R., Henderson G., Hawley T.S.,
RA   Reimold A.M., Glimcher L.H., Baumann H., Malek L.T., Hawley R.G.;
RT   "Identification of c-myc promoter-binding protein and X-box binding protein
RT   1 as interleukin-6 target genes in human multiple myeloma cells.";
RL   Int. J. Oncol. 15:173-178(1999).
RN   [12]
RP   FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11460154; DOI=10.1038/35085509;
RA   Reimold A.M., Iwakoshi N.N., Manis J., Vallabhajosyula P.,
RA   Szomolanyi-Tsuda E., Gravallese E.M., Friend D., Grusby M.J., Alt F.,
RA   Glimcher L.H.;
RT   "Plasma cell differentiation requires the transcription factor XBP-1.";
RL   Nature 412:300-307(2001).
RN   [13]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO MAJOR AFFECTIVE DISORDER TYPE 7.
RX   PubMed=12949534; DOI=10.1038/ng1235;
RA   Kakiuchi C., Iwamoto K., Ishiwata M., Bundo M., Kasahara T., Kusumi I.,
RA   Tsujita T., Okazaki Y., Nanko S., Kunugi H., Sasaki T., Kato T.;
RT   "Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar
RT   disorder.";
RL   Nat. Genet. 35:171-175(2003).
RN   [14]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=15466483; DOI=10.1083/jcb.200406136;
RA   Sriburi R., Jackowski S., Mori K., Brewer J.W.;
RT   "XBP1: a link between the unfolded protein response, lipid biosynthesis,
RT   and biogenesis of the endoplasmic reticulum.";
RL   J. Cell Biol. 167:35-41(2004).
RN   [15]
RP   INDUCTION (ISOFORM 2).
RX   PubMed=17110785; DOI=10.1247/csf.06016;
RA   Yoshida H., Nadanaka S., Sato R., Mori K.;
RT   "XBP1 is critical to protect cells from endoplasmic reticulum stress:
RT   evidence from Site-2 protease-deficient Chinese hamster ovary cells.";
RL   Cell Struct. Funct. 31:117-125(2006).
RN   [16]
RP   FUNCTION (ISOFORMS 1 AND 2), INTERACTION WITH XBP1 ISOFORM 2 (ISOFORM 1),
RP   SUBCELLULAR LOCATION (ISOFORMS 1 AND 2), INDUCTION (ISOFORMS 1 AND 2),
RP   STRESS-MEDIATED DOWN-REGULATION (ISOFORM 1), AND DOMAIN (ISOFORMS 1 AND 2).
RX   PubMed=16461360; DOI=10.1083/jcb.200508145;
RA   Yoshida H., Oku M., Suzuki M., Mori K.;
RT   "pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein
RT   response activator pXBP1(S) in mammalian ER stress response.";
RL   J. Cell Biol. 172:565-575(2006).
RN   [17]
RP   INTERACTION WITH ATF6 (ISOFORM 2).
RX   PubMed=17765680; DOI=10.1016/j.devcel.2007.07.018;
RA   Yamamoto K., Sato T., Matsui T., Sato M., Okada T., Yoshida H., Harada A.,
RA   Mori K.;
RT   "Transcriptional induction of mammalian ER quality control proteins is
RT   mediated by single or combined action of ATF6alpha and XBP1.";
RL   Dev. Cell 13:365-376(2007).
RN   [18]
RP   UNCONVENTIONAL ALTERNATIVE SPLICING (ISOFORM 2).
RX   PubMed=19622636; DOI=10.1242/jcs.040584;
RA   Uemura A., Oku M., Mori K., Yoshida H.;
RT   "Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the
RT   mammalian unfolded protein response.";
RL   J. Cell Sci. 122:2877-2886(2009).
RN   [19]
RP   FUNCTION (ISOFORM 1), SUBCELLULAR LOCATION (ISOFORMS 1 AND 2), TOPOLOGY
RP   (ISOFORM 1), DOMAIN (ISOFORM 1), AND MUTAGENESIS OF TRP-189; VAL-193;
RP   LEU-194; LEU-196; ILE-198 AND TRP-205.
RX   PubMed=19394296; DOI=10.1016/j.molcel.2009.02.033;
RA   Yanagitani K., Imagawa Y., Iwawaki T., Hosoda A., Saito M., Kimata Y.,
RA   Kohno K.;
RT   "Cotranslational targeting of XBP1 protein to the membrane promotes
RT   cytoplasmic splicing of its own mRNA.";
RL   Mol. Cell 34:191-200(2009).
RN   [20]
RP   FUNCTION (ISOFORM 2), DNA-BINDING (ISOFORMS 1 AND 2), INDUCTION (ISOFORMS 1
RP   AND 2), AND TISSUE SPECIFICITY (ISOFORMS 1 AND 2).
RX   PubMed=19416856; DOI=10.1073/pnas.0903197106;
RA   Zeng L., Zampetaki A., Margariti A., Pepe A.E., Alam S., Martin D.,
RA   Xiao Q., Wang W., Jin Z.G., Cockerill G., Mori K., Li Y.S., Hu Y.,
RA   Chien S., Xu Q.;
RT   "Sustained activation of XBP1 splicing leads to endothelial apoptosis and
RT   atherosclerosis development in response to disturbed flow.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8326-8331(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH PIK3R1 (ISOFORM 2), AND SUBCELLULAR LOCATION
RP   (ISOFORMS 1 AND 2).
RX   PubMed=20348923; DOI=10.1038/nm.2121;
RA   Winnay J.N., Boucher J., Mori M.A., Ueki K., Kahn C.R.;
RT   "A regulatory subunit of phosphoinositide 3-kinase increases the nuclear
RT   accumulation of X-box-binding protein-1 to modulate the unfolded protein
RT   response.";
RL   Nat. Med. 16:438-445(2010).
RN   [22]
RP   ACETYLATION BY EP300 (ISOFORM 2), DEACETYLATION BY SIRT1 (ISOFORM 2), AND
RP   SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=20955178; DOI=10.1042/bj20101293;
RA   Wang F.M., Chen Y.J., Ouyang H.J.;
RT   "Regulation of unfolded protein response modulator XBP1s by acetylation and
RT   deacetylation.";
RL   Biochem. J. 433:245-252(2011).
RN   [23]
RP   FUNCTION (ISOFORM 1), DOMAIN (ISOFORM 1), AND MUTAGENESIS OF LEU-246;
RP   SER-255 AND TRP-256.
RX   PubMed=21233347; DOI=10.1126/science.1197142;
RA   Yanagitani K., Kimata Y., Kadokura H., Kohno K.;
RT   "Translational pausing ensures membrane targeting and cytoplasmic splicing
RT   of XBP1u mRNA.";
RL   Science 331:586-589(2011).
RN   [24]
RP   FUNCTION (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, AND INDUCTION (ISOFORM
RP   2).
RX   PubMed=23529610; DOI=10.1161/circulationaha.112.001337;
RA   Zeng L., Xiao Q., Chen M., Margariti A., Martin D., Ivetic A., Xu H.,
RA   Mason J., Wang W., Cockerill G., Mori K., Li J.Y., Chien S., Hu Y., Xu Q.;
RT   "Vascular endothelial cell growth-activated XBP1 splicing in endothelial
RT   cells is crucial for angiogenesis.";
RL   Circulation 127:1712-1722(2013).
RN   [25]
RP   FUNCTION (ISOFORM 2), DNA-BINDING (ISOFORM 2), AND INDUCTION (ISOFORM 2).
RX   PubMed=23184933; DOI=10.1074/jbc.m112.412783;
RA   Margariti A., Li H., Chen T., Martin D., Vizcay-Barrena G., Alam S.,
RA   Karamariti E., Xiao Q., Zampetaki A., Zhang Z., Wang W., Jiang Z., Gao C.,
RA   Ma B., Chen Y.G., Cockerill G., Hu Y., Xu Q., Zeng L.;
RT   "XBP1 mRNA splicing triggers an autophagic response in endothelial cells
RT   through BECLIN-1 transcriptional activation.";
RL   J. Biol. Chem. 288:859-872(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-68, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   FUNCTION (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=25280941; DOI=10.1016/j.cellsig.2014.09.018;
RA   Li H., Chen X., Gao Y., Wu J., Zeng F., Song F.;
RT   "XBP1 induces snail expression to promote epithelial-to-mesenchymal
RT   transition and invasion of breast cancer cells.";
RL   Cell. Signal. 27:82-89(2015).
RN   [28]
RP   FUNCTION (ISOFORMS 1 AND 2), INTERACTION WITH DERL1; HM13; RNF139 AND XBP1
RP   ISOFORM 2 (ISOFORM 1), TOPOLOGY (ISOFORM 1), PROTEOLYTIC CLEAVAGE (ISOFORM
RP   1), SUBCELLULAR LOCATION (ISOFORM 1 AND CYTOPLASMIC FORM), UBIQUITINATION
RP   (ISOFORM 1 AND LUMINAL FORM), STRESS-MEDIATED DOWN-REGULATION (ISOFORM 2),
RP   AND MUTAGENESIS OF GLN-197; GLN-199; SER-200; SER-203; THR-212; CYS-215 AND
RP   ARG-232.
RX   PubMed=25239945; DOI=10.15252/embj.201488208;
RA   Chen C.Y., Malchus N.S., Hehn B., Stelzer W., Avci D., Langosch D.,
RA   Lemberg M.K.;
RT   "Signal peptide peptidase functions in ERAD to cleave the unfolded protein
RT   response regulator XBP1u.";
RL   EMBO J. 33:2492-2506(2014).
RN   [29]
RP   FUNCTION (ISOFORM 1), DNA-BINDING (ISOFORMS 1 AND 2), INTERACTION WITH
RP   HDAC3 AND AKT1 (ISOFORM 1), SUBCELLULAR LOCATION (ISOFORM 1), AND INDUCTION
RP   (ISOFORMS 1 AND 2).
RX   PubMed=25190803; DOI=10.1074/jbc.m114.571984;
RA   Martin D., Li Y., Yang J., Wang G., Margariti A., Jiang Z., Yu H.,
RA   Zampetaki A., Hu Y., Xu Q., Zeng L.;
RT   "Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from
RT   oxidative stress through interaction with histone deacetylase 3.";
RL   J. Biol. Chem. 289:30625-30634(2014).
RN   [30]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-12.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [31]
RP   VARIANT LYS-232.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
CC   -!- FUNCTION: Functions as a transcription factor during endoplasmic
CC       reticulum (ER) stress by regulating the unfolded protein response
CC       (UPR). Required for cardiac myogenesis and hepatogenesis during
CC       embryonic development, and the development of secretory tissues such as
CC       exocrine pancreas and salivary gland (By similarity). Involved in
CC       terminal differentiation of B lymphocytes to plasma cells and
CC       production of immunoglobulins (PubMed:11460154). Modulates the cellular
CC       response to ER stress in a PIK3R-dependent manner (PubMed:20348923).
CC       Binds to the cis-acting X box present in the promoter regions of major
CC       histocompatibility complex class II genes (PubMed:8349596). Involved in
CC       VEGF-induced endothelial cell (EC) proliferation and retinal blood
CC       vessel formation during embryonic development but also for angiogenesis
CC       in adult tissues under ischemic conditions. Functions also as a major
CC       regulator of the UPR in obesity-induced insulin resistance and type 2
CC       diabetes for the management of obesity and diabetes prevention (By
CC       similarity). {ECO:0000250|UniProtKB:O35426,
CC       ECO:0000269|PubMed:11460154, ECO:0000269|PubMed:20348923,
CC       ECO:0000269|PubMed:8349596}.
CC   -!- FUNCTION: [Isoform 1]: Plays a role in the unconventional cytoplasmic
CC       splicing processing of its own mRNA triggered by the endoplasmic
CC       reticulum (ER) transmembrane endoribonuclease ENR1: upon ER stress, the
CC       emerging XBP1 polypeptide chain, as part of a mRNA-ribosome-nascent
CC       chain (R-RNC) complex, cotranslationally recruits its own unprocessed
CC       mRNA through transient docking to the ER membrane and translational
CC       pausing, therefore facilitating efficient IRE1-mediated XBP1 mRNA
CC       isoform 2 production (PubMed:19394296, PubMed:21233347). In endothelial
CC       cells (EC), associated with KDR, promotes IRE1-mediated XBP1 mRNA
CC       isoform 2 productions in a vascular endothelial growth factor (VEGF)-
CC       dependent manner, leading to EC proliferation and angiogenesis
CC       (PubMed:23529610). Functions as a negative feed-back regulator of the
CC       potent transcription factor XBP1 isoform 2 protein levels through
CC       proteasome-mediated degradation, thus preventing the constitutive
CC       activation of the ER stress response signaling pathway
CC       (PubMed:16461360, PubMed:25239945). Inhibits the transactivation
CC       activity of XBP1 isoform 2 in myeloma cells (By similarity). Acts as a
CC       weak transcriptional factor (PubMed:8657566). Together with HDAC3,
CC       contributes to the activation of NFE2L2-mediated HMOX1 transcription
CC       factor gene expression in a PI(3)K/mTORC2/Akt-dependent signaling
CC       pathway leading to EC survival under disturbed flow/oxidative stress
CC       (PubMed:25190803). Binds to the ER stress response element (ERSE) upon
CC       ER stress (PubMed:11779464). Binds to the consensus 5'-
CC       GATGACGTG[TG]N(3)[AT]T-3' sequence related to cAMP responsive element
CC       (CRE)-like sequences (PubMed:8657566). Binds the Tax-responsive element
CC       (TRE) present in the long terminal repeat (LTR) of T-cell leukemia
CC       virus type 1 (HTLV-I) and to the TPA response elements (TRE)
CC       (PubMed:2321018, PubMed:2196176, PubMed:1903538, PubMed:8657566).
CC       Associates preferentially to the HDAC3 gene promoter region in a static
CC       flow-dependent manner (PubMed:25190803). Binds to the CDH5/VE-cadherin
CC       gene promoter region (PubMed:19416856). {ECO:0000250|UniProtKB:O35426,
CC       ECO:0000269|PubMed:11779464, ECO:0000269|PubMed:16461360,
CC       ECO:0000269|PubMed:1903538, ECO:0000269|PubMed:19394296,
CC       ECO:0000269|PubMed:19416856, ECO:0000269|PubMed:21233347,
CC       ECO:0000269|PubMed:2196176, ECO:0000269|PubMed:2321018,
CC       ECO:0000269|PubMed:23529610, ECO:0000269|PubMed:25190803,
CC       ECO:0000269|PubMed:25239945, ECO:0000269|PubMed:8657566}.
CC   -!- FUNCTION: [Isoform 2]: Functions as a stress-inducible potent
CC       transcriptional activator during endoplasmic reticulum (ER) stress by
CC       inducing unfolded protein response (UPR) target genes via binding to
CC       the UPR element (UPRE). Up-regulates target genes encoding ER
CC       chaperones and ER-associated degradation (ERAD) components to enhance
CC       the capacity of productive folding and degradation mechanism,
CC       respectively, in order to maintain the homeostasis of the ER under ER
CC       stress (PubMed:11779464, PubMed:25239945). Plays a role in the
CC       production of immunoglobulins and interleukin-6 in the presence of
CC       stimuli required for plasma cell differentiation (By similarity).
CC       Induces phospholipid biosynthesis and ER expansion (PubMed:15466483).
CC       Contributes to the VEGF-induced endothelial cell (EC) growth and
CC       proliferation in a Akt/GSK-dependent and/or -independent signaling
CC       pathway, respectively, leading to beta-catenin nuclear translocation
CC       and E2F2 gene expression (PubMed:23529610). Promotes umbilical vein EC
CC       apoptosis and atherosclerotisis development in a caspase-dependent
CC       signaling pathway, and contributes to VEGF-induced EC proliferation and
CC       angiogenesis in adult tissues under ischemic conditions
CC       (PubMed:19416856, PubMed:23529610). Involved in the regulation of
CC       endostatin-induced autophagy in EC through BECN1 transcriptional
CC       activation (PubMed:23184933). Plays a role as an oncogene by promoting
CC       tumor progression: stimulates zinc finger protein SNAI1 transcription
CC       to induce epithelial-to-mesenchymal (EMT) transition, cell migration
CC       and invasion of breast cancer cells (PubMed:25280941). Involved in
CC       adipocyte differentiation by regulating lipogenic gene expression
CC       during lactation. Plays a role in the survival of both dopaminergic
CC       neurons of the substantia nigra pars compacta (SNpc), by maintaining
CC       protein homeostasis and of myeloma cells. Increases insulin sensitivity
CC       in the liver as a response to a high carbohydrate diet, resulting in
CC       improved glucose tolerance. Improves also glucose homeostasis in an ER
CC       stress- and/or insulin-independent manner through both binding and
CC       proteasome-induced degradation of the transcription factor FOXO1, hence
CC       resulting in suppression of gluconeogenic genes expression and in a
CC       reduction of blood glucose levels. Controls the induction of de novo
CC       fatty acid synthesis in hepatocytes by regulating the expression of a
CC       subset of lipogenic genes in an ER stress- and UPR-independent manner
CC       (By similarity). Associates preferentially to the HDAC3 gene promoter
CC       region in a disturbed flow-dependent manner (PubMed:25190803). Binds to
CC       the BECN1 gene promoter region (PubMed:23184933). Binds to the CDH5/VE-
CC       cadherin gene promoter region (PubMed:19416856). Binds to the ER stress
CC       response element (ERSE) upon ER stress (PubMed:11779464). Binds to the
CC       5'-CCACG-3' motif in the PPARG promoter (By similarity).
CC       {ECO:0000250|UniProtKB:O35426, ECO:0000269|PubMed:11779464,
CC       ECO:0000269|PubMed:15466483, ECO:0000269|PubMed:19416856,
CC       ECO:0000269|PubMed:23184933, ECO:0000269|PubMed:23529610,
CC       ECO:0000269|PubMed:25190803, ECO:0000269|PubMed:25239945,
CC       ECO:0000269|PubMed:25280941}.
CC   -!- SUBUNIT: Isoform 2 interacts with SIRT1. Isoform 2 interacts with
CC       PIK3R1 and PIK3R2; the interactions are direct and induce translocation
CC       of XBP1 isoform 2 into the nucleus and the unfolded protein response
CC       (UPR) XBP1-dependent target genes activation in a ER stress- and/or
CC       insulin-dependent but PI3K-independent manner. Isoform 2 interacts with
CC       FOXO1; the interaction is direct and leads to FOXO1 ubiquitination and
CC       degradation via the proteasome pathway in hepatocytes (By similarity).
CC       Isoform 1 interacts with HM13 (PubMed:25239945). Isoform 1 interacts
CC       with RNF139; the interaction induces ubiquitination and degradation of
CC       isoform 1 (PubMed:25239945). Isoform 1 interacts (via luminal domain)
CC       with DERL1; the interaction obviates the need for ectodomain shedding
CC       prior HM13/SPP-mediated XBP1 isoform 1 cleavage (PubMed:25239945).
CC       Isoform 1 interacts with isoform 2; the interaction sequesters isoform
CC       2 from the nucleus and enhances isoform 2 degradation in the cytoplasm
CC       (PubMed:16461360, PubMed:25239945). Isoform 1 interacts with HDAC3 and
CC       AKT1; the interactions occur in endothelial cell (EC) under disturbed
CC       flow (PubMed:25190803). Isoform 1 interacts with the oncoprotein FOS
CC       (PubMed:1903538). Isoform 2 interacts with ATF6; the interaction occurs
CC       in a ER stress-dependent manner and is required for DNA binding to the
CC       unfolded protein response element (UPRE) (PubMed:17765680). Isoform 2
CC       interacts with PIK3R1; the interaction is direct and induces
CC       translocation of XBP1 isoform 2 into the nucleus and the unfolded
CC       protein response (UPR) XBP1-dependent target genes activation in a ER
CC       stress- and/or insulin-dependent but PI3K-independent manner
CC       (PubMed:20348923). {ECO:0000250|UniProtKB:O35426,
CC       ECO:0000269|PubMed:16461360, ECO:0000269|PubMed:17765680,
CC       ECO:0000269|PubMed:1903538, ECO:0000269|PubMed:20348923,
CC       ECO:0000269|PubMed:25190803, ECO:0000269|PubMed:25239945}.
CC   -!- INTERACTION:
CC       P17861; P18850: ATF6; NbExp=2; IntAct=EBI-6942961, EBI-852157;
CC       P17861; Q9NS37: CREBZF; NbExp=2; IntAct=EBI-6942961, EBI-632965;
CC       P17861; Q16665: HIF1A; NbExp=3; IntAct=EBI-6942961, EBI-447269;
CC       P17861; Q13404: UBE2V1; NbExp=3; IntAct=EBI-6942961, EBI-1050671;
CC       P17861-1; Q8TCT9: HM13; NbExp=2; IntAct=EBI-7631279, EBI-347472;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:23529610}. Note=Colocalizes with ERN1 and KDR in
CC       the endoplasmic reticulum in endothelial cells in a vascular
CC       endothelial growth factor (VEGF)-dependent manner (PubMed:23529610).
CC       {ECO:0000269|PubMed:23529610}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus
CC       {ECO:0000269|PubMed:16461360, ECO:0000269|PubMed:19394296}. Cytoplasm
CC       {ECO:0000269|PubMed:16461360, ECO:0000269|PubMed:19394296,
CC       ECO:0000269|PubMed:20348923, ECO:0000269|PubMed:25190803}. Endoplasmic
CC       reticulum membrane {ECO:0000269|PubMed:25239945}; Single-pass type II
CC       membrane protein {ECO:0000269|PubMed:25239945}. Endoplasmic reticulum
CC       membrane {ECO:0000303|PubMed:25239945}; Peripheral membrane protein
CC       {ECO:0000303|PubMed:25239945}. Membrane {ECO:0000269|PubMed:19394296};
CC       Peripheral membrane protein {ECO:0000303|PubMed:19394296}. Note=Shows
CC       no preferential localization to either the nucleus or the cytoplasm (By
CC       similarity). Shuttles between the nucleus and the cytoplasm in a CRM1-
CC       dependent manner (PubMed:16461360). Localizes predominantly at the
CC       endoplasmic reticulum membrane as a membrane-spanning protein; whereas
CC       may be only marginally localized on the cytosolic side of the ER
CC       membrane as a peripheral membrane (PubMed:19394296, PubMed:25190803).
CC       {ECO:0000250|UniProtKB:O35426, ECO:0000269|PubMed:16461360,
CC       ECO:0000269|PubMed:19394296, ECO:0000269|PubMed:25190803}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus
CC       {ECO:0000269|PubMed:16461360, ECO:0000269|PubMed:19394296,
CC       ECO:0000269|PubMed:20348923, ECO:0000269|PubMed:20955178}. Cytoplasm
CC       {ECO:0000250|UniProtKB:O35426}. Note=Localizes predominantly in the
CC       nucleus. Colocalizes in the nucleus with SIRT1. Translocates into the
CC       nucleus in a PIK3R-, ER stress-induced- and/or insulin-dependent manner
CC       (By similarity). {ECO:0000250|UniProtKB:O35426}.
CC   -!- SUBCELLULAR LOCATION: [X-box-binding protein 1, cytoplasmic form]:
CC       Cytoplasm {ECO:0000269|PubMed:25239945}. Nucleus
CC       {ECO:0000269|PubMed:25239945}. Note=Localizes in the cytoplasm and
CC       nucleus after HM13/SPP-mediated intramembranaire proteolytic cleavage
CC       of isoform 1 (PubMed:25239945). {ECO:0000269|PubMed:25239945}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Unprocessed XBP-1 {ECO:0000305}, XBP-1U
CC       {ECO:0000303|PubMed:11779464}, XBP1u {ECO:0000303|PubMed:19394296};
CC         IsoId=P17861-1; Sequence=Displayed;
CC       Name=2; Synonyms=Processed XBP-1 {ECO:0000305}, XBP-1S
CC       {ECO:0000303|PubMed:11779464}, XBP1s {ECO:0000303|PubMed:19394296};
CC         IsoId=P17861-2; Sequence=VSP_012936;
CC   -!- TISSUE SPECIFICITY: Expressed in plasma cells in rheumatoid synovium
CC       (PubMed:11460154). Over-expressed in primary breast cancer and
CC       metastatic breast cancer cells (PubMed:25280941). Isoform 1 and isoform
CC       2 are expressed at higher level in proliferating as compared to
CC       confluent quiescent endothelial cells (PubMed:19416856).
CC       {ECO:0000269|PubMed:11460154, ECO:0000269|PubMed:19416856,
CC       ECO:0000269|PubMed:25280941}.
CC   -!- INDUCTION: Isoform 1 is up-regulated at the recovery phase of the
CC       endoplasmic reticulum (ER) stress response and isoform 2 is up-
CC       regulated early during the ER stress response and gradually decreased
CC       at later phase of ER stress (PubMed:16461360). Isoform 1 and isoform 2
CC       are down-regulated by laminar flow but up-regulated by disturbed flow
CC       in umbilical vein endothelial cells in vitro (at protein level)
CC       (PubMed:19416856). Down-regulated by the B-cell-specific transcription
CC       factor PAX5 (PubMed:8627152). Up-regulated by interleukin IL-6 in
CC       myeloma cells (PubMed:10375612). Up-regulated during plasma-cell
CC       differentiation, either through the CD40 receptor signaling pathway or
CC       mitogens such as lipopolysaccharide (LPS) (PubMed:11460154). Isoform 1
CC       and isoform 2 are down-regulated by laminar flow but up-regulated by
CC       disturbed flow in umbilical vein endothelial cells in vitro
CC       (PubMed:25190803). Isoform 2 is up-regulated early during the ER stress
CC       response in a ATF6-dependent manner (PubMed:11779464, PubMed:17110785,
CC       PubMed:16461360). Isoform 2 is up-regulated by endostatin in a ERN1-
CC       dependent manner (PubMed:23184933). Isoform 2 is transiently up-
CC       regulated by the mitogenic vascular endothelial growth factor (VEGF) in
CC       endothelial cells (PubMed:23529610). {ECO:0000269|PubMed:10375612,
CC       ECO:0000269|PubMed:11460154, ECO:0000269|PubMed:11779464,
CC       ECO:0000269|PubMed:16461360, ECO:0000269|PubMed:17110785,
CC       ECO:0000269|PubMed:19416856, ECO:0000269|PubMed:23184933,
CC       ECO:0000269|PubMed:23529610, ECO:0000269|PubMed:25190803,
CC       ECO:0000269|PubMed:8627152}.
CC   -!- DOMAIN: Isoform 1 and isoform 2 N-terminus domains are necessary for
CC       nuclear localization targeting. Isoform 1 C-terminus domain confers
CC       localization to the cytoplasm and is sufficient to impose rapid
CC       degradation (By similarity). Isoform 1 transmembrane signal-anchor
CC       domain is necessary for its own mRNA to be recruited to the endoplasmic
CC       reticulum (ER) which will undergo unconventional ERN1-dependent
CC       splicing in response to ER stress (PubMed:19394296, PubMed:21233347).
CC       Isoform 1 N-terminus and C-terminus regions are necessary for DNA-
CC       binding and weak transcriptional activity, respectively. Isoform 2 N-
CC       terminus and C-terminus regions are necessary for DNA-binding and
CC       strong transcriptional activity upon ER stress, respectively
CC       (PubMed:11779464, PubMed:8657566). Isoform 2 C-terminus region contains
CC       a nuclear exclusion signal (NES) at positions 186 through 208. Isoform
CC       2 C-terminus region contains a degradation domain at positions 209
CC       through 261 (PubMed:16461360). {ECO:0000250|UniProtKB:O35426,
CC       ECO:0000269|PubMed:11779464, ECO:0000269|PubMed:16461360,
CC       ECO:0000269|PubMed:19394296, ECO:0000269|PubMed:21233347,
CC       ECO:0000269|PubMed:8657566}.
CC   -!- PTM: [Isoform 2]: Acetylated by EP300; acetylation positively regulates
CC       the transcriptional activity of XBP1 isoform 2 (PubMed:20955178).
CC       Isoform 2 is deacetylated by SIRT1; deacetylation negatively regulates
CC       the transcriptional activity of XBP1 isoform 2 (PubMed:20955178).
CC       {ECO:0000269|PubMed:20955178, ECO:0000305|PubMed:20955178}.
CC   -!- PTM: [Isoform 1]: Ubiquitinated, leading to proteasome-mediated
CC       degradation in response to ER stress (PubMed:11779464, PubMed:16461360,
CC       PubMed:25239945). {ECO:0000250|UniProtKB:O35426,
CC       ECO:0000269|PubMed:11779464, ECO:0000269|PubMed:16461360,
CC       ECO:0000269|PubMed:25239945}.
CC   -!- PTM: X-box-binding protein 1, cytoplasmic form and luminal form are
CC       produced by intramembrane proteolytic cleavage of ER membrane-anchored
CC       isoform 1 triggered by HM13/SPP in a DERL1-RNF139-dependent and
CC       VCP/p97-independent manner. X-box-binding protein 1, luminal form is
CC       ubiquitinated leading to proteasomal degradation (PubMed:25239945).
CC       {ECO:0000269|PubMed:25239945}.
CC   -!- DISEASE: Major affective disorder 7 (MAFD7) [MIM:612371]: A major
CC       psychiatric disorder that is characterized by severe mood swings, with
CC       fluctuation between two abnormal mood states (manic or major depressive
CC       episode). Mania is accompanied by symptoms of euphoria, irritability,
CC       or excitation, whereas depression is associated with low mood and
CC       decreased motivation and energy. Note=Disease susceptibility may be
CC       associated with variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Potent transcriptional activator. Induced
CC       by unconventional ERN1-dependent splicing in response to endoplasmic
CC       reticulum stress (PubMed:11779464, PubMed:19622636, PubMed:19394296).
CC       ENR1 cleaves a 26-bp fragment causing a frameshift of the mRNA
CC       transcript (PubMed:11779464). {ECO:0000269|PubMed:11779464,
CC       ECO:0000269|PubMed:19394296, ECO:0000269|PubMed:19622636}.
CC   -!- SIMILARITY: Belongs to the bZIP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31627; AAA36031.1; -; mRNA.
DR   EMBL; X55543; CAA39149.1; -; Genomic_DNA.
DR   EMBL; L13850; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB076383; BAB82981.1; -; mRNA.
DR   EMBL; AB076384; BAB82982.1; -; mRNA.
DR   EMBL; CR456611; CAG30497.1; -; mRNA.
DR   EMBL; Z93930; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000938; AAH00938.1; -; mRNA.
DR   EMBL; BC012841; AAH12841.1; -; mRNA.
DR   EMBL; BC015709; AAH15709.1; -; mRNA.
DR   CCDS; CCDS13847.1; -. [P17861-1]
DR   PIR; A36299; A36299.
DR   RefSeq; NP_001073007.1; NM_001079539.1. [P17861-2]
DR   RefSeq; NP_005071.2; NM_005080.3. [P17861-1]
DR   PDB; 6R5Q; EM; 3.00 A; 1=237-260.
DR   PDB; 6R6G; EM; 3.70 A; 1=237-260.
DR   PDB; 6R6P; EM; 3.10 A; 1=237-260.
DR   PDB; 6R7Q; EM; 3.90 A; 1=237-260.
DR   PDBsum; 6R5Q; -.
DR   PDBsum; 6R6G; -.
DR   PDBsum; 6R6P; -.
DR   PDBsum; 6R7Q; -.
DR   SMR; P17861; -.
DR   BioGRID; 113331; 39.
DR   DIP; DIP-41692N; -.
DR   IntAct; P17861; 16.
DR   MINT; P17861; -.
DR   STRING; 9606.ENSP00000216037; -.
DR   BindingDB; P17861; -.
DR   ChEMBL; CHEMBL1741176; -.
DR   iPTMnet; P17861; -.
DR   PhosphoSitePlus; P17861; -.
DR   SwissPalm; P17861; -.
DR   BioMuta; XBP1; -.
DR   DMDM; 60416406; -.
DR   EPD; P17861; -.
DR   jPOST; P17861; -.
DR   MassIVE; P17861; -.
DR   MaxQB; P17861; -.
DR   PaxDb; P17861; -.
DR   PeptideAtlas; P17861; -.
DR   PRIDE; P17861; -.
DR   ProteomicsDB; 53522; -. [P17861-1]
DR   ProteomicsDB; 53523; -. [P17861-2]
DR   Antibodypedia; 10221; 698 antibodies.
DR   DNASU; 7494; -.
DR   Ensembl; ENST00000216037; ENSP00000216037; ENSG00000100219. [P17861-1]
DR   Ensembl; ENST00000344347; ENSP00000343155; ENSG00000100219. [P17861-2]
DR   Ensembl; ENST00000611155; ENSP00000481170; ENSG00000100219. [P17861-2]
DR   GeneID; 7494; -.
DR   KEGG; hsa:7494; -.
DR   UCSC; uc062cvg.1; human. [P17861-1]
DR   CTD; 7494; -.
DR   DisGeNET; 7494; -.
DR   GeneCards; XBP1; -.
DR   HGNC; HGNC:12801; XBP1.
DR   HPA; ENSG00000100219; Tissue enhanced (pancreas, salivary gland).
DR   MalaCards; XBP1; -.
DR   MIM; 194355; gene.
DR   MIM; 612371; phenotype.
DR   neXtProt; NX_P17861; -.
DR   OpenTargets; ENSG00000100219; -.
DR   PharmGKB; PA37400; -.
DR   VEuPathDB; HostDB:ENSG00000100219.16; -.
DR   eggNOG; KOG4005; Eukaryota.
DR   GeneTree; ENSGT00390000017751; -.
DR   HOGENOM; CLU_069050_0_0_1; -.
DR   InParanoid; P17861; -.
DR   OMA; KSCEQEC; -.
DR   OrthoDB; 1269901at2759; -.
DR   PhylomeDB; P17861; -.
DR   TreeFam; TF319837; -.
DR   PathwayCommons; P17861; -.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes. [P17861-2]
DR   Reactome; R-HSA-381070; IRE1alpha activates chaperones. [P17861-2]
DR   Reactome; R-HSA-381183; ATF6 (ATF6-alpha) activates chaperone genes. [P17861-2]
DR   SignaLink; P17861; -.
DR   SIGNOR; P17861; -.
DR   BioGRID-ORCS; 7494; 9 hits in 1017 CRISPR screens.
DR   ChiTaRS; XBP1; human.
DR   GeneWiki; XBP1; -.
DR   GenomeRNAi; 7494; -.
DR   Pharos; P17861; Tchem.
DR   PRO; PR:P17861; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P17861; protein.
DR   Bgee; ENSG00000100219; Expressed in body of pancreas and 142 other tissues.
DR   ExpressionAtlas; P17861; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:LIFEdb.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0030331; F:estrogen receptor binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0060612; P:adipose tissue development; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0036500; P:ATF6-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; ISS:UniProtKB.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0071332; P:cellular response to fructose stimulus; ISS:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISS:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; ISS:UniProtKB.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0031670; P:cellular response to nutrient; ISS:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; ISS:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0035356; P:cellular triglyceride homeostasis; ISS:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISS:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0001889; P:liver development; ISS:UniProtKB.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1900102; P:negative regulation of endoplasmic reticulum unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:UniProtKB.
DR   GO; GO:0060394; P:negative regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048666; P:neuron development; ISS:UniProtKB.
DR   GO; GO:0006996; P:organelle organization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:1903071; P:positive regulation of ER-associated ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000347; P:positive regulation of hepatocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0031062; P:positive regulation of histone methylation; IDA:UniProtKB.
DR   GO; GO:0002639; P:positive regulation of immunoglobulin production; IDA:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISS:UniProtKB.
DR   GO; GO:1903489; P:positive regulation of lactation; ISS:UniProtKB.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0071073; P:positive regulation of phospholipid biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:1900100; P:positive regulation of plasma cell differentiation; IDA:UniProtKB.
DR   GO; GO:1901985; P:positive regulation of protein acetylation; IDA:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IDA:UniProtKB.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006990; P:positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response; IDA:UniProtKB.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0035470; P:positive regulation of vascular wound healing; IDA:BHF-UCL.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:UniProtKB.
DR   GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0055092; P:sterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR004827; bZIP.
DR   Pfam; PF07716; bZIP_2; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Angiogenesis;
KW   Apoptosis; Autophagy; Cleavage on pair of basic residues; Cytoplasm;
KW   Developmental protein; Differentiation; DNA-binding; Endoplasmic reticulum;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Myogenesis; Nucleus;
KW   Oncogene; Phosphoprotein; Protein transport; Reference proteome;
KW   Signal-anchor; Stress response; Transcription; Transcription regulation;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation;
KW   Unfolded protein response.
FT   CHAIN           1..261
FT                   /note="X-box-binding protein 1"
FT                   /id="PRO_0000076543"
FT   CHAIN           1..193
FT                   /note="X-box-binding protein 1, cytoplasmic form"
FT                   /evidence="ECO:0000303|PubMed:25239945"
FT                   /id="PRO_0000431891"
FT   CHAIN           196..261
FT                   /note="X-box-binding protein 1, luminal form"
FT                   /evidence="ECO:0000303|PubMed:25239945"
FT                   /id="PRO_0000431892"
FT   TOPO_DOM        1..185
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   TRANSMEM        186..203
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25239945,
FT                   ECO:0000303|PubMed:25239945"
FT   TOPO_DOM        204..261
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   DOMAIN          70..133
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          72..94
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          75..92
FT                   /note="Nuclear localization signal (NLS); in isoforms 1 and
FT                   isoform 2"
FT                   /evidence="ECO:0000269|PubMed:16461360"
FT   REGION          98..133
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          235..261
FT                   /note="Necessary for the translational pausing of its own
FT                   mRNA"
FT                   /evidence="ECO:0000269|PubMed:21233347"
FT   SITE            194..195
FT                   /note="Cleavage; by HM13/SPP"
FT                   /evidence="ECO:0000303|PubMed:25239945"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         68
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         167..261
FT                   /note="LRLRAPLQQVQAQLSPLQNISPWILAVLTLQIQSLISCWAFWTTWTQSCSSN
FT                   ALPQSLPAWRSSQRSTQKDPVPYQPPFLCQWGRHQPSWKPLMN -> GAGPVVTPPEHL
FT                   PMDSGGIDSSDSESDILLGILDNLDPVMFFKCPSPEPASLEELPEVYPEGPSSLPASLS
FT                   LSVGTSSAKLEAINELIRFDHIYTKPLVLEIPSETESQANVVVKIEEAPLSPSENDHPE
FT                   FIVSVKEEPVEDDLVPELGISNLLSSSHCPKPSSCLLDAYSDCGYGGSLSPFSDMSSLL
FT                   GVNHSWEDTFANELFPQLISV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11779464"
FT                   /id="VSP_012936"
FT   VARIANT         12
FT                   /note="D -> V (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035998"
FT   VARIANT         232
FT                   /note="R -> K (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs1379560430)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033023"
FT   MUTAGEN         189
FT                   /note="W->E: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with E-193 and D-196."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         193
FT                   /note="V->E: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with E-189 and D-196."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         194
FT                   /note="L->E: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with D-198 and E-205."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         196
FT                   /note="L->D: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with E-189 and E-193."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         197
FT                   /note="Q->L: Inhibits HM13/SPP-mediated degradation of
FT                   XBP1; when associated with L-199; L-200 and L-203."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         198
FT                   /note="I->D: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with E-194 and E-205."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         199
FT                   /note="Q->L: Inhibits HM13/SPP-mediated degradation of
FT                   XBP1; when associated with L-197; L-200 and L-203."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         200
FT                   /note="S->L: Inhibits HM13/SPP-mediated degradation of
FT                   XBP1; when associated with L-197; L-199 and L-203."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         203
FT                   /note="S->L: Inhibits HM13/SPP-mediated degradation of
FT                   XBP1; when associated with L-197; L-199 and L-200."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         205
FT                   /note="W->E: Reduces endoplasmic reticulum localization of
FT                   its own mRNA; when associated with E-194 and D-198."
FT                   /evidence="ECO:0000269|PubMed:19394296"
FT   MUTAGEN         212
FT                   /note="T->N: Does not induce glycosylation."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         215
FT                   /note="C->N: Induces glycosylation."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         232
FT                   /note="R->N: Induces glycosylation."
FT                   /evidence="ECO:0000269|PubMed:25239945"
FT   MUTAGEN         246
FT                   /note="L->A: Reduces translational pausing, membrane
FT                   targeting and cytoplasmic splicing of its own mRNA."
FT                   /evidence="ECO:0000269|PubMed:21233347"
FT   MUTAGEN         255
FT                   /note="S->A: Increases translational pausing of its own
FT                   mRNA."
FT                   /evidence="ECO:0000269|PubMed:21233347"
FT   MUTAGEN         256
FT                   /note="W->A: Reduces translational pausing, membrane
FT                   targeting and cytoplasmic splicing of its own mRNA."
FT                   /evidence="ECO:0000269|PubMed:21233347"
FT   CONFLICT        33..35
FT                   /note="GQA -> AR (in Ref. 1; AAA36031)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        130
FT                   /note="N -> T (in Ref. 3; L13850)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="L -> F (in Ref. 3; L13850)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   261 AA;  28695 MW;  A4EF69EEE0D344A6 CRC64;
     MVVVAAAPNP ADGTPKVLLL SGQPASAAGA PAGQALPLMV PAQRGASPEA ASGGLPQARK
     RQRLTHLSPE EKALRRKLKN RVAAQTARDR KKARMSELEQ QVVDLEEENQ KLLLENQLLR
     EKTHGLVVEN QELRQRLGMD ALVAEEEAEA KGNEVRPVAG SAESAALRLR APLQQVQAQL
     SPLQNISPWI LAVLTLQIQS LISCWAFWTT WTQSCSSNAL PQSLPAWRSS QRSTQKDPVP
     YQPPFLCQWG RHQPSWKPLM N
//
